A. Fleischer

A four-domain framework for secondary immunodeficiency after CAR T-cell and T-cell-engaging antibody therapy

Chimeric antigen receptor (CAR) T-cell therapies and T-cell-engaging antibodies have transformed the treatment of hematologic malignancies but can induce prolonged, overlapping, and dynamically evolving immune deficits that are not adequately captured by hypogammaglobulinemia alone. Infection susceptibility reflects th...